IDL Biotech AB har haft uppföljningsmöte med FDA | IDL Biotech
IDL Biotech

CLOSE MENU

October 2019

IDL Biotech AB har haft uppföljningsmöte med FDA

I juli lämnade IDL Biotech in underlag, så kallad Pre-submission request, till amerikanska FDA (Food and Drug Administration) för att kunna få ett framtida godkännande för försäljning i USA av UBC® Rapid, bolagets snabbtest för blåscancer. Idag genomfördes det första uppföljningsmötet med FDA.

Läs nyheten här

IDL Biotech signs distributor agreement in Ghana

IDL Biotech continues to expand in Africa. IDL Biotech has signed a distributor agreement with Res Health Consult Ltd covering Ghana. The agreement covers the sale of TUBEX® TF.

IDL Biotech includes additional clinics in its ongoing multicenter study for UBC® Rapid in Sweden.

IDL Biotech currently has a number of ongoing clinical studies both internationally and in Sweden, with the aim of demonstrating the clinical benefit of UBC® Rapid in bladder cancer and having the test included as a complement in the follow-up of patients with bladder cancer who are classified as high risk.

IDL Biotech

Skip this intro